Aldebaran Financial Inc. Buys 169 Shares of Eli Lilly and Company (NYSE:LLY)

Aldebaran Financial Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 15.5% in the fourth quarter, HoldingsChannel reports. The fund owned 1,262 shares of the company’s stock after acquiring an additional 169 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of Aldebaran Financial Inc.’s investment portfolio, making the stock its 20th largest holding. Aldebaran Financial Inc.’s holdings in Eli Lilly and Company were worth $977,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Highline Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock valued at $35,000 after acquiring an additional 20 shares in the last quarter. FPC Investment Advisory Inc. raised its position in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $48,000. Compass Financial Services Inc acquired a new position in Eli Lilly and Company in the 4th quarter valued at $50,000. Finally, Fiduciary Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $58,000. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on LLY shares. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Morgan Stanley decreased their price target on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 9th. Guggenheim decreased their target price on Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Two analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,012.00.

Eli Lilly and Company Stock Down 2.6 %

Eli Lilly and Company stock opened at $818.18 on Tuesday. The firm has a 50 day moving average price of $827.99 and a two-hundred day moving average price of $818.92. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The firm has a market cap of $775.77 billion, a price-to-earnings ratio of 69.87, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.